187 related articles for article (PubMed ID: 37991046)
1. Novel therapies for pediatric acute lymphoblastic leukemia.
Graff Z; Burke MJ; Gossai N
Curr Opin Pediatr; 2024 Feb; 36(1):64-70. PubMed ID: 37991046
[TBL] [Abstract][Full Text] [Related]
2. The future of cellular immunotherapy for childhood leukemia.
Bonifant CL; Tasian SK
Curr Opin Pediatr; 2020 Feb; 32(1):13-25. PubMed ID: 31851053
[TBL] [Abstract][Full Text] [Related]
3. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
[TBL] [Abstract][Full Text] [Related]
4. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
5. Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ; Narendran A; Neville KA
Drugs; 2013 Apr; 73(5):439-61. PubMed ID: 23568274
[TBL] [Abstract][Full Text] [Related]
6. Targeted Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia-Therapy and Toxicity Mechanisms.
Lejman M; Kuśmierczuk K; Bednarz K; Ostapińska K; Zawitkowska J
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575992
[TBL] [Abstract][Full Text] [Related]
7. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
DuVall AS; Wesevich A; Larson RA
Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
[TBL] [Abstract][Full Text] [Related]
8. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
9. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
10. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
Dinner S; Lee D; Liedtke M
Leuk Lymphoma; 2014 Aug; 55(8):1715-24. PubMed ID: 24251864
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
13. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
Hochberg J; El-Mallawany NK; Cairo MS
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
[TBL] [Abstract][Full Text] [Related]
14. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Pierro J; Hogan LE; Bhatla T; Carroll WL
Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
[TBL] [Abstract][Full Text] [Related]
15. Pediatric Acute Lymphoblastic Leukemia Emerging Therapies-From Pathway to Target.
Ivanov AV; Alecsa MS; Popescu R; Starcea MI; Mocanu AM; Rusu C; Miron IC
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902091
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in pediatric acute lymphoblastic leukemia.
Inaba H; Pui CH
Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
[TBL] [Abstract][Full Text] [Related]
17. Molecular-based and antibody-based targeted pharmacological approaches in childhood acute lymphoblastic leukemia.
Tardif M; Souza A; Krajinovic M; Bittencourt H; Tran TH
Expert Opin Pharmacother; 2021 Oct; 22(14):1871-1887. PubMed ID: 34011251
[No Abstract] [Full Text] [Related]
18. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
[TBL] [Abstract][Full Text] [Related]
19. The treatment of adolescents and young adults with acute lymphoblastic leukemia.
Advani AS; Hanna R
Leuk Lymphoma; 2020 Jan; 61(1):18-26. PubMed ID: 31452423
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
Ronson A; Tvito A; Rowe JM
Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
